Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Shares of I-Mab (NASDAQ:IMAB) jumped 15% in midday trading Monday after the biotech company said it plans to focus on ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.

Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...